Fulltext

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

Nabors, L. Burt ; Fink, Karen L. ; Mikkelsen, Tom ; Grujicic, Danica ; Tarnawski, Rafal ; Nam, Do Hyun ; Mazurkiewicz, Maria ; Salacz, Michael ; Ashby, Lynn ; Zagonel, Vittorina ; Depenni, Roberta ; Perry, James R. ; Hicking, Christine ; Picard, Martin ; Hegi, Monika E. ; Lhermitte, Benoit ; Reardon, David A.

In: Neuro-Oncology, 2015, vol. 17, no. 5, p. 708-717

Add to personal list
    Title
    • Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
    Author
    • Nabors, L. Burt. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Fink, Karen L.. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Mikkelsen, Tom. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Grujicic, Danica. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Tarnawski, Rafal. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Nam, Do Hyun. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Mazurkiewicz, Maria. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Salacz, Michael. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Ashby, Lynn. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Zagonel, Vittorina. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Depenni, Roberta. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Perry, James R.. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Hicking, Christine. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Picard, Martin. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Hegi, Monika E.. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Lhermitte, Benoit. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    • Reardon, David A.. University of Alabama at Birmingham, Birmingham, Alabama, Dallas, Texas, Detroit, Michigan, Clinic for Neurosurgery, Clinical Center of Serbia, Belgrade,, Gliwice, Seoul, Lublin, Kansas City, Missouri, Phoenix, Arizona, Padova, Modena, Toronto, Ontario, Darmstadt, Department of Clinical Neurosciences, Lausanne, Institute of Pathology, Lausanne, Boston, Massachusetts, Serbia, Poland, South Korea, Poland, Italy, Italy, Canada, Germany, Switzerland, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Neuro-Oncology, 2015, vol. 17, no. 5, p. 708-717. Oxford University Press
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:289318
    Summary
    Background Survival outcomes for patients with glioblastoma remain poor, particularly for patients with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter. This phase II, randomized, open-label, multicenter trial investigated the efficacy and safety of 2 dose regimens of the selective integrin inhibitor cilengitide combined with standard chemoradiotherapy in patients with newly diagnosed glioblastoma and an unmethylated MGMT promoter. Methods Overall, 265 patients were randomized (1:1:1) to standard cilengitide (2000 mg 2×/wk; n = 88), intensive cilengitide (2000 mg 5×/wk during wk 1−6, thereafter 2×/wk; n = 88), or a control arm (chemoradiotherapy alone; n = 89). Cilengitide was administered intravenously in combination with daily temozolomide (TMZ) and concomitant radiotherapy (RT; wk 1−6), followed by TMZ maintenance therapy (TMZ/RT→TMZ). The primary endpoint was overall survival; secondary endpoints included progression-free survival, pharmacokinetics, and safety and tolerability. Results Median overall survival was 16.3 months in the standard cilengitide arm (hazard ratio [HR], 0.686; 95% CI: 0.484, 0.972; P = .032) and 14.5 months in the intensive cilengitide arm (HR, 0.858; 95% CI: 0.612, 1.204; P = .3771) versus 13.4 months in the control arm. Median progression-free survival assessed per independent review committee was 5.6 months (HR, 0.822; 95% CI: 0.595, 1.134) and 5.9 months (HR, 0.794; 95% CI: 0.575, 1.096) in the standard and intensive cilengitide arms, respectively, versus 4.1 months in the control arm. Cilengitide was well tolerated. Conclusions Standard and intensive cilengitide dose regimens were well tolerated in combination with TMZ/RT→TMZ. Inconsistent overall survival and progression-free survival outcomes and a limited sample size did not allow firm conclusions regarding clinical efficacy in this exploratory phase II study